# A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers

> **NCT04983368** · PHASE1,PHASE2 · COMPLETED · sponsor: **Actinogen Medical** · enrollment: 107 (actual)

## Conditions studied

- Mild Cognitive Impairment
- Alzheimer's Disease

## Interventions

- **DRUG:** Xanamem® 5 mg
- **DRUG:** Placebo
- **DRUG:** Xanamem® 10 mg

## Key facts

- **NCT ID:** NCT04983368
- **Lead sponsor:** Actinogen Medical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-30
- **Primary completion:** 2022-02-11
- **Final completion:** 2022-02-11
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2025-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04983368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04983368, "A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT04983368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*